Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
Abstract Hepatocellular carcinoma (HCC) is a deadly malignancy with high genetic heterogeneity. TP53 mutation and c-MET activation are frequent events in human HCCs. Here, we discovered that the simultaneous mutations in TP53 and activation of c-MET occur in ~20% of human HCCs, and these patients sh...
Main Authors: | Yi Zhou, Guofei Cui, Hongwei Xu, Joanne Chun, Doris Yang, Zheng Zhang, Lihui Yang, Jingxiao Wang, Meijuan Wan, Diego F. Calvisi, Shumei Lin, Xin Chen, Haichuan Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-07-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-023-05958-y |
Similar Items
-
Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis
by: Sophie Klemm, et al.
Published: (2023-11-01) -
Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01) -
Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis
by: Chun Wang, et al.
Published: (2023-12-01) -
Overexpression of Human Syndecan-1 Protects against the Diethylnitrosamine-Induced Hepatocarcinogenesis in Mice
by: Andrea Reszegi, et al.
Published: (2021-03-01) -
TP53 in Myelodysplastic Syndromes
by: Yan Jiang, et al.
Published: (2021-10-01)